reports
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Still No Decisive Breakout as SPX Tests 5783 The S&P 500 (SPX) remains just below 5783, which is the upper-end of an important target/resistance area we have discussed for over a month (5670-5783). 5670 was the prior all-time high set in July, while 5783 is 2% above 5670. It is hard to call it a "decisive" breakout if the SPX is not even 2% above its prior high, and, importantly, in 2007, the SPX made a top after climbing 1-2% above its prior high. To reiterate, the 2007 topping analog has trac...
WITN WIPRO LTD
VEC VECTRUS
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
LDOS LEIDOS HOLDINGS INC.
KRO KRONOS WORLDWIDE INC.
IT GARTNER INC.
HCKT THE HACKETT GROUP
EQIX EQUINIX INC.
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
CRS CARPENTER TECHNOLOGY CORPORATION
CACI CACI INTERNATIONAL INC CLASS A
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ATI ALLEGHENY TECHNOLOGIES INCORPORATED
USAP UNIVERSAL STAINLESS & ALLOY PRODUCTS INC.
GIB.A CGI INC. CLASS A
TSE TRINSEO PLC
INFY INFOSYS LTD
MMS AMUNDI MSCI EMU SMALL CAP ESG CTB NET ZERO AMBITION
AVNT AVANT BRANDS INC.
Savara Announces Patient Journey Map for People Living with Autoimmune...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of an abstract for poster presentation at the CHEST 2024 Annual Meeting, taking place October 6-9 in Boston. The Company is also sponsoring an Industry Symposium at the meeting. Details are as follows: Accepted Abstract Title: “A Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)” Poster Session: Diffuse Lung Disease Abstracts Posters (D) Date and Time: October 8, 2024, 1:45 - 2:30pm ...
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On September 25, 2024, Savara's Board of Directors granted the inducement awards to Braden Parker, who joined the Company as Chief Commercial Officer on September 24, 2024. The inducement awards consist of options to purchase 170,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 85,000 shares of the Company’s common stock. These equity awards were granted under the...
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhala...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the Savara Early Access Program, a molgramostim Expanded Access Program (EAP) for patients with aPAP. The program enables physicians to request molgramostim for eligible aPAP patients in select geographies where the product is not commercially available and in compliance with local regulatory requirements. The Savara Early Access Program has been reviewed and allowed to proceed by the U.S. Food and Drug Administration (FDA), and it i...
Savara Appoints Braden Parker as Chief Commercial Officer, Effective I...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointment of Braden Parker as Chief Commercial Officer, effective immediately. Mr. Parker is a seasoned global commercial leader with more than 25 years of experience in the healthcare and biotech industry. Throughout his career, he has developed and executed global commercial plans, including market expansion activities, built high-performance teams, and launched multiple successful rare disease products. Mr. Parker is responsi...
Savara to Host Analyst and Investor Webinar on September 30, 2024
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, will host an analyst and investor webinar on September 30, 2024 from 8:30-9:30 a.m. ET to present data from the Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution (molgramostim) in autoimmune Pulmonary Alveolar Proteinosis (aPAP) and provide updates on the global commercial landscape and the Company’s market development work. The webinar will feature presentations from Savara's management team and the following key opinion leaders: ...
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgr...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that new data from the Phase 3 IMPALA-2 clinical trial of molgramostim in patients with autoimmune Pulmonary Alveolar Proteinosis (aPAP) were presented at the European Respiratory Society (ERS) Congress 2024 in Vienna, Austria. The poster from this presentation can be found . As previously , the IMPALA-2 trial met its primary endpoint, achieving statistical significance in change from baseline in hemoglobin-adjusted percent predicte...
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On September 5, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 20,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 20,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc....
Savara to Present at the H.C. Wainwright 26th Annual Global Investment...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024 at 10:00am ET/7:00am PT. A live webcast of the presentation will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granu...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
VEC VECTRUS
TRU TRANSUNION
RUN SUNRUN INC.
OSIS OSI SYSTEMS INC.
LINC LINCOLN EDUCATIONAL SERVICES
LDOS LEIDOS HOLDINGS INC.
KTOS KRATOS DEFENSE & SECURITY SOLUTIONS INC.
IMAX IMAX CORPORATION
ERIE ERIE INDEMNITY COMPANY CLASS A
CUBE CUBESMART
ACGL ARCH CAPITAL GROUP LTD.
BBSI BARRETT BUSINESS SERVICES INC.
AVH AVITA MEDICAL CDI
HRTG HERITAGE INSURANCE HOLDINGS INC.
TATT TAT TECHNOLOGIES LTD.
HRB H&R BLOCK INC.
COKE COCA-COLA CONSOLIDATED INC.
FEIM FREQUENCY ELECTRONICS INC.
HLNE HAMILTON LANE INCORPORATED CLASS A
RDFN REDFIN CORPORATION
TIGO MILLICOM INTERNATIONAL CELLULAR S.A.
HOV HOVNANIAN ENTERPRISES INC. CLASS A
PLMR PALOMAR HOLDINGS
LC LENDINGCLUB CORP
SG SWEETGREEN INC
HGTY HAGERTY INC
IGIC INTERNATIONAL GENERAL INS HLDGS LTD
CLMT CALUMET INC
MHH MAJESTIC HORIZON HOLDINGS LTD ORD
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On August 15, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 20,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 20,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 20...
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molg...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an abstract for poster presentation at the European Respiratory Society (ERS) Congress 2024, taking place September 7-11, 2024, in Vienna, Austria. The Company is also sponsoring an Industry Symposium at the Congress. Details are as follows: Accepted Abstract Title: “Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life (HRQoL) in Patients with Autoimmune Pulmonary Alve...
Savara Reports Second Quarter 2024 Financial Results and Provides Busi...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2024 and provided a business update. Recent Business Highlights Reported positive top line results from IMPALA-2, a pivotal, Phase 3 clinical trial of molgramostim nebulizer solution (molgramostim) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) — Statistically significant improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide...
Cannae Holdings, Inc. Announces Second Quarter 2024 Financial Results
LAS VEGAS--(BUSINESS WIRE)-- Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) has released its second quarter 2024 financial results by posting them to its website. Please visit the Cannae website at to view the second quarter 2024 financial results, which are included in its Letter to Shareholders. Conference Call As previously announced, Cannae will host a conference call, today, August 8, 2024 at 5:00pm (Eastern Time), to discuss its second quarter 2024 results. The conference call can be accessed by dialing 1-800-245-3047 (domestic) or 1-203-518-9765 (international) and ...
Leidos Holdings Inc: 2 directors
Two Directors at Leidos Holdings Inc bought/sold 2,771 shares at between 145.038USD and 145.230USD. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...
Cannae Holdings, Inc. Announces Quarterly Cash Dividend of $0.12
LAS VEGAS--(BUSINESS WIRE)-- Cannae Holdings, Inc. (NYSE: CNNE) today announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share. The dividend will be payable September 30, 2024, to shareholders of record as of September 16, 2024. About Cannae Holdings, Inc. We primarily acquire interests in operating companies and are actively engaged in managing and operating a core group of those companies. We believe that our long-term ownership and active involvement in the management and operations of companies helps maximize the value of those businesses for our ...
Cannae Holdings, Inc. Announces Second Quarter 2024 Earnings Release D...
LAS VEGAS--(BUSINESS WIRE)-- Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) today announced that the Company will release its second quarter 2024 financial results after the market close on Thursday, August 8, 2024. The Company will also hold a conference call to discuss its financial results at 5:00 pm (Eastern Time) on the same day. The conference call can be accessed by dialing 1-800-245-3047 (domestic) or 1-203-518-9765 (international) and asking for the Cannae Holdings Second Quarter 2024 Earnings Call. A telephonic replay will be available at the conclusion of the call ...
Savara Announces Pricing of $100.0 Million Underwritten Offering of Co...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, for total gross proceeds of approximately $100.0 million. All of the securities to be sold in the offering are being sold by Savara. The offering included the following investors: Bain Capital Life Sciences, Farallon Capital Management, Frazier Life Sciences, Wellington Management, N...
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achiev...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced positive results from the pivotal, Phase 3 IMPALA-2 clinical trial. IMPALA-2 is a 48-week, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of molgramostim 300 mcg administered once daily by inhalation with matching placebo in adult patients with aPAP (). Molgramostim is an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The trial met its primary endpoi...
Savara to Host Investor Call to Discuss Top Line Results From Pivotal ...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top line results from the pivotal, Phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of molgramostim, an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with aPAP. The Company plans to issue a press release sharing the top line results at approximately 6:30a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.